Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report)’s stock price hit a new 52-week low during trading on Tuesday. The stock traded as low as $4.50 and last traded at $4.4660, with a volume of 28,416 shares traded. The stock had previously closed at $4.72.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, September 21st. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.
Check Out Our Latest Stock Report on Regencell Bioscience
Regencell Bioscience Price Performance
Regencell Bioscience (NASDAQ:RGC – Get Free Report) last posted its quarterly earnings data on Wednesday, October 7th. The company reported ($0.01) earnings per share for the quarter.
Institutional Investors Weigh In On Regencell Bioscience
An institutional investor recently raised its stake in Regencell Bioscience stock. Bank of America Corp DE raised its position in Regencell Bioscience Holdings Limited (NASDAQ:RGC – Free Report) by 59,113.8% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 17,172 shares of the company’s stock after buying an additional 17,143 shares during the quarter. Bank of America Corp DE’s holdings in Regencell Bioscience were worth $437,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 0.13% of the company’s stock.
Regencell Bioscience Company Profile
Regencell Bioscience Holdings Limited is a Hong Kong-based, clinical-stage bioscience company focused on researching and developing traditional Chinese medicine (TCM) treatments. Its main area of focus is neurocognitive disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The company is developing TCM-based treatment protocols and formulations for these conditions. Its work centers on research and clinical evaluation; Regencell is not a developer of established, widely marketed prescription drugs for these disorders.
Further Reading
- Five stocks we like better than Regencell Bioscience
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
